Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TEVA | 3 | neutral | 2/10 | Dov Bergwerk filed a Form 3 initial statement of beneficial ownership upon becoming Interim Chief Legal Officer of Teva | Oct 8, 2026 |
| BHST | 6-K | neutral | 4/10 | BioHarvest Sciences announced a key milestone with partner Tate & Lyle in their next-generation sweetener development pr | Oct 8, 2026 |
| SXTC | 6-K | bearish | 6/10 | China SXT Pharmaceuticals announced a $12 million registered direct offering of 8,000,000 Class A ordinary shares at $1. | Oct 8, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a 6-K disclosing that independent Non-Executive Director Wendy Becker CBE has been appointed as a Non-Executiv | Oct 8, 2026 |
| NNVC | DEF 14A | neutral | 3/10 | NanoViricides filed its definitive proxy statement for the 2026 Annual Meeting, seeking re-election of three directors ( | Oct 8, 2026 |
| KPTI | SC 13G/A | bearish | 5/10 | Acorn Bioventures, L.P. and affiliated entities filed an amended Schedule 13G disclosing an aggregate beneficial ownersh | Oct 8, 2026 |
| PCRX | 144 | neutral | 2/10 | Lauren Riker, an officer of Pacira BioSciences, filed a Form 144 on October 8, 2026, indicating intent to sell 6,000 sha | Oct 8, 2026 |
| RDY | 6-K | neutral | 3/10 | Dr. Reddy's disclosed that the USFDA conducted a Pre-Approval Inspection (PAI) at its FTO-11 facility in Pydibhimavaram, | Oct 8, 2026 |
| PCRX | 8-K | bullish | 7/10 | Pacira BioSciences has entered into a definitive agreement to be acquired by Viatris for $36.50 per share in cash, repre | Oct 8, 2026 |
| HELP | 6-K | neutral | 4/10 | Helus Pharma announced an investor presentation scheduled for October 21, 2026, to discuss its Phase 3 MDD candidate HLP | Oct 8, 2026 |
| PCRX | SC TO-C | bullish | 7/10 | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash, representing an aggregate e | Oct 8, 2026 |
| VIR | 8-K | neutral | 4/10 | Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-maske | Oct 8, 2026 |
| VTRS | 8-K | bullish | 7/10 | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash, representing an aggregate e | Oct 8, 2026 |
| BIAF | 8-K | bullish | 4/10 | bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its C | Oct 8, 2026 |
| ICLR | 6-K | neutral | 2/10 | ICON plc filed a 6-K announcing the schedule for its Q3 2026 earnings release and conference call. The earnings will be | Oct 8, 2026 |
| QNTM | 6-K | neutral | 4/10 | Quantum BioPharma announced that the U.S. District Court for the Southern District of New York consolidated its direct a | Oct 8, 2026 |
| VALN | 6-K | neutral | 3/10 | Valneva announced that the UK MHRA revoked the marketing authorization for its chikungunya vaccine IXCHIQ following a be | Oct 8, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced the publication of a patent application in Japan covering 3-MMC-based treatment for dyskine | Oct 8, 2026 |
| CUE | SC 13G/A | neutral | 4/10 | Mark E. Strome and affiliated entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of 644,91 | Oct 8, 2026 |
| SXTC | 6-K | bearish | 5/10 | China SXT Pharmaceuticals entered into a securities purchase agreement on October 7, 2026, for a $3 million private plac | Oct 8, 2026 |
| IAM | S-1/A | neutral | 5/10 | Iambic Therapeutics, an AI-driven clinical-stage biopharmaceutical company, filed Amendment No. 1 to its S-1 for an IPO | Oct 8, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, | Oct 8, 2026 |
| RNA | 8-K | bearish | 6/10 | Atrium Therapeutics announced a ~$50M private placement, selling 5,170,384 common shares at $7.93/share and pre-funded w | Oct 8, 2026 |
| CATX | 8-K | bullish | 6/10 | Perspective Therapeutics announced FDA Fast Track Designation for PSV359, its FAP-targeted alpha-particle therapy for so | Oct 8, 2026 |
| ADXN | 6-K | bullish | 5/10 | Addex Therapeutics announced via 6-K that its spin-out Neurosterix completed Phase 1 studies of NTX-253 (M4 PAM for schi | Oct 8, 2026 |
| ARGX | 6-K | mixed | 6/10 | argenx reported positive Phase 2 topline results for FB102 in celiac disease, meeting the primary endpoint (p=0.0176) an | Oct 8, 2026 |
| SBFM | EFFECT | bearish | 6/10 | The SEC declared effective Sunshine Biopharma's S-1 registration (File No. 333-299274) on October 7, 2026, enabling the | Oct 8, 2026 |
| CYDY | EFFECT | bearish | 6/10 | The SEC declared CytoDyn's S-3 shelf registration (File No. 333-299150) effective on October 7, 2026. This allows the co | Oct 8, 2026 |
| BMRA | EFFECT | neutral | 4/10 | Biomerica's S-3 shelf registration (File No. 333-299133) became effective on October 7, 2026, enabling the company to co | Oct 8, 2026 |
| BMRA | EFFECT | neutral | 4/10 | The SEC declared effective Biomerica's S-3 shelf registration (File No. 333-299120) on October 7, 2026. This allows the | Oct 8, 2026 |